A 43-year-old woman with systemic sclerosis developed generalized pruritic erythematous papules. Systemic sclerosis was diagnosed based on a fever, arthritis, and sclerodactyly with positive findings for anti-nuclear antibody 1280x (discrete pattern) and anti-centromere antibody. While the arthritis improved, painful pruritic papules with pustular elements appeared on both arms and buttocks ([Picture 1](#g001){ref-type="fig"}), and some bruising was noted over the thighs ([Picture 2](#g002){ref-type="fig"}) after 5 doses of subcutaneously injected tocilizumab (162 mg every 2 weeks). The rash failed to respond to a topical steroid and antifungal ointment but promptly improved after the discontinuation of tocilizumab. Tocilizumab is a humanized antihuman interleukin-6 (IL-6) receptor monoclonal antibody. Cutaneous reactions to tocilizumab have included psoriasiform rash and leukocytoclastic vascultis ([@B1]). The paradoxical increase in circulating IL-6 after the inhibition of the IL-6 receptor by tocilizumab may result in the intraepidermal recruitment of neutrophils and keratinocyte hypertrophy, which is seen in cases of psoriasiform rash and other forms of skin reactions ([@B2]).
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